Chemo Cheat Sheets Help Nurses During Drug Delivery

Elizabeth Aronson, MSN, FNP-BCN, OCN, discusses how the recent approvals of elranatamab and talquetamab are changing the treatment landscape for patients with multiple myeloma.

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Jennifer Cargile, MEd, CCC-SLP, shares some signs and symptoms of cancer-related cognitive impairment that the oncology nurse should be looking out for.

Heather Santone breaks down some of the barriers that geriatric patients with cancer face—and how nurse navigators can help them overcome these obstacles.

There is room to improve drug adherence, patient education, and adverse event (AE) management for interstitial lung disease and cardiac AEs, according to Patricia Jakel, RN, MN, AOCN.

Tucatinib was first approved by the FDA for the treatment of patients with HER2-positive advanced unresectable or metastatic breast cancer in combination with trastuzumab and capecitabine on April 17, 2020.